{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:21:08Z","timestamp":1793931668057,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jaci.2025.12.1008","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T16:20:19Z","timestamp":1768234819000},"page":"858-867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["First-in-human study for londamocitinib (AZD4604), an inhaled selective JAK1 inhibitor"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4696-643X","authenticated-orcid":false,"given":"Tina","family":"Jellesmark Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Riff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zala","family":"Jevnikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Belvisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"M\u00e4enp\u00e4\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szil\u00e1rd","family":"Nemes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Forte Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajkumar","family":"Chetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder P.S.","family":"Dosanjh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Zingmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriakos V.","family":"Konstantinidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rod","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2025.12.1008_bib2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1183\/09031936.98.12051209","article-title":"Difficult asthma","volume":"12","author":"Barnes","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2025.12.1008_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jaci.2006.10.025","article-title":"Severe asthma: lessons from the Severe Asthma Research Program","volume":"119","author":"Wenzel","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.12.1008_bib4","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2025.12.1008_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nri.2017.86","article-title":"Innate lymphoid cells: major players in inflammatory diseases","volume":"17","author":"Ebbo","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2025.12.1008_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00528-2020","article-title":"Treatment options in type-2 low asthma","volume":"57","author":"Hinks","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2025.12.1008_bib7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2\u2013driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.12.1008_bib8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaci.2021.08.013","article-title":"JAK inhibitors for asthma","volume":"148","author":"Georas","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.12.1008_bib9","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1172\/JCI0215786","article-title":"JAK-STAT signaling in asthma","volume":"109","author":"Pernis","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2025.12.1008_bib10","doi-asserted-by":"crossref","first-page":"19455","DOI":"10.1073\/pnas.1008271107","article-title":"Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7\u2013induced signaling","volume":"107","author":"Rochman","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2025.12.1008_bib11","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/1873-3468.14201","article-title":"Making sense of IL-6 signalling cues in pathophysiology","volume":"596","author":"Millrine","year":"2022","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jaci.2025.12.1008_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12931-020-01505-x","article-title":"Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?","volume":"21","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2025.12.1008_bib13","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.12.1008_bib14","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2025.12.1008_bib15","doi-asserted-by":"crossref","first-page":"13400","DOI":"10.1021\/acs.jmedchem.3c00554","article-title":"Discovery of the potent and selective inhaled Janus kinase 1 inhibitor AZD4604 and its preclinical characterization","volume":"66","author":"Nilsson","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2025.12.1008_bib16","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.2147\/DDDT.S354291","article-title":"Characterization of selective and potent JAK1 inhibitors intended for the inhaled treatment of asthma","volume":"16","author":"Nilsson","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jaci.2025.12.1008_bib18","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.12.1008_bib19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1055\/s-0042-1743290","article-title":"FeNO in asthma","volume":"43","author":"Loewenthal","year":"2022","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.12.1008_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1165\/rcmb.2006-0419OC","article-title":"Measurement of IL-13\u2013induced iNOS-derived gas phase nitric oxide in human bronchial epithelial cells","volume":"37","author":"Suresh","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaci.2025.12.1008_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126658","article-title":"Inhaled Janus kinase (JAK) inhibitors for the treatment of asthma","volume":"29","author":"Zak","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jaci.2025.12.1008_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaci.2021.02.042","article-title":"Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: a randomized, controlled, proof-of-activity trial","volume":"148","author":"Braithwaite","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2025.12.1008_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2022.102133","article-title":"Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation","volume":"75","author":"Chen","year":"2022","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaci.2025.12.1008_bib24","series-title":"Single and multiple ascending dose study of TD-8236 by inhalation","year":"2021"},{"key":"10.1016\/j.jaci.2025.12.1008_bib25","article-title":"Clinically relevant reductions in FeNO reported after 10-day treatment with KN-002 in subjects with mild asthma","volume":"209","author":"Singh","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.12.1008_bib26","series-title":"A study in healthy volunteers and patients with mild asthma to investigate the safety, anti-inflammatory effect of inhaled AZD0449","year":"2023"},{"key":"10.1016\/j.jaci.2025.12.1008_bib27","article-title":"The safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor: results from part C of a first-in-human study in participants with moderate to severe asthma","volume":"205","author":"Pfeifer","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2025.12.1008_bib28","doi-asserted-by":"crossref","first-page":"AB98","DOI":"10.1016\/j.jaci.2023.11.323","article-title":"AZD4604, an inhaled, selective JAK1 inhibitor reduces fractional exhaled nitric oxide in patients with mild asthma; a randomized, single-blind phase 1 study","volume":"153","author":"Jensen","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl 64","key":"10.1016\/j.jaci.2025.12.1008_bib29","article-title":"Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics","volume":"58","author":"Pfeifer","year":"2021","journal-title":"Eur Respir J"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926000023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926000023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:39:28Z","timestamp":1778722768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926000023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0091674926000023"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2025.12.1008","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human study for londamocitinib (AZD4604), an inhaled selective JAK1 inhibitor","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2025.12.1008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}